Unstable angina - NSTEMI guidelines - Revision history

Danbot: Add verified PubMed references (PMIDs 27026020)

2026-03-22T10:59:09Z

Add verified PubMed references (PMIDs 27026020)

← Revisión anterior		Revisión del 10:59 22 mar 2026
Línea 1:		Línea 1:
	==Summary of Class I Guidelines==		==Summary of Class I Guidelines==
	*[[Aspirin]] should be initiated as soon as possible and continued indefinitely in patients who tolerate it. ([[EBQ:Evidence Levels\|Level A]])		*[[Aspirin]] should be initiated as soon as possible and continued indefinitely in patients who tolerate it. ([[EBQ:Evidence Levels\|Level A]]) <ref>Levine GN, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016 Sep 6;134(10):e123-55. PMID 27026020</ref>
	*[[Clopidogrel]] loading dose should be initiated as soon as possible in patients unable to tolerate aspirin. ([[EBQ:Evidence Levels\|Level B]])		*[[Clopidogrel]] loading dose should be initiated as soon as possible in patients unable to tolerate aspirin. ([[EBQ:Evidence Levels\|Level B]])
	*Medium/High risk patients in whom initial invasive strategy is planned should receive dual therapy (Level A) including aspirin (Level A) and:		*Medium/High risk patients in whom initial invasive strategy is planned should receive dual therapy (Level A) including aspirin (Level A) and:

Danbot: Danbot moved page Unstable Angina - NSTEMI Guidelines to Unstable angina - NSTEMI guidelines without leaving a redirect: Naming convention: first word capitalized, subsequent words lowercase

2026-03-22T05:36:02Z

Danbot moved page Unstable Angina - NSTEMI Guidelines to Unstable angina - NSTEMI guidelines without leaving a redirect: Naming convention: first word capitalized, subsequent words lowercase

← Revisión anterior	Revisión del 05:36 22 mar 2026
(Sin diferencias)

ClaireLewis at 17:55, 19 September 2019

2019-09-19T17:55:09Z

Jonwarren: /* Summary of Class IIb Guidelines */

2018-06-17T23:45:19Z

Summary of Class IIb Guidelines

← Revisión anterior		Revisión del 23:45 17 jun 2018
Línea 27:		Línea 27:
	==Summary of Class IIb Guidelines==		==Summary of Class IIb Guidelines==

	*Abciximab should not be administered to patients in whom PCI is not planned. ([[EBQ:Evidence Levels\|Level A]])		*[[Abciximab]] should not be administered to patients in whom PCI is not planned. ([[EBQ:Evidence Levels\|Level A]])
	*Low risk patients for ischemic events (TIMI risk score 2) or at high risk of bleeding and who are already receiving ASA and clopidogrel, upstream GP IIb/IIIa inhibitors are not recommended. ([[EBQ:Evidence Levels\|Level B]])		*Low risk patients for ischemic events (TIMI risk score 2) or at high risk of bleeding and who are already receiving ASA and clopidogrel, upstream GP IIb/IIIa inhibitors are not recommended. ([[EBQ:Evidence Levels\|Level B]])

Rossdonaldson1: Text replacement - "troponin " to "troponin "

2016-12-04T14:33:21Z

Text replacement - "troponin " to "troponin "

← Revisión anterior		Revisión del 14:33 4 dic 2016
Línea 21:		Línea 21:
	*If an initial conservative strategy is selected, it may be reasonable to add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy.19,20 ([[EBQ:Evidence Levels\|Level B]])		*If an initial conservative strategy is selected, it may be reasonable to add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy.19,20 ([[EBQ:Evidence Levels\|Level B]])
	*Prasugrel may be considered for administration promptly upon presentation if PCI is planned, before definition of coronary anatomy if both the risk for bleeding is low and the need for CABG is considered unlikely. ([[EBQ:Evidence Levels\|Level C]])		*Prasugrel may be considered for administration promptly upon presentation if PCI is planned, before definition of coronary anatomy if both the risk for bleeding is low and the need for CABG is considered unlikely. ([[EBQ:Evidence Levels\|Level C]])
	*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for		*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated [[troponin]] levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for
	bleeding. ([[EBQ:Evidence Levels\|Level B]])		bleeding. ([[EBQ:Evidence Levels\|Level B]])
	*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600mg, followed by a higher maintenance dose of 150mg daily for 6 days, then 75mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])		*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600mg, followed by a higher maintenance dose of 150mg daily for 6 days, then 75mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])

Neil.m.young: Text replacement - "5 mg" to "5mg"

2016-07-26T22:44:58Z

Text replacement - "5 mg" to "5mg"

← Revisión anterior		Revisión del 22:44 26 jul 2016
Línea 23:		Línea 23:
	*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for		*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for
	bleeding. ([[EBQ:Evidence Levels\|Level B]])		bleeding. ([[EBQ:Evidence Levels\|Level B]])
	*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600mg, followed by a higher maintenance dose of 150mg daily for 6 days, then ~~75 mg~~ daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])		*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600mg, followed by a higher maintenance dose of 150mg daily for 6 days, then 75mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])

	==Summary of Class IIb Guidelines==		==Summary of Class IIb Guidelines==

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-26T10:23:55Z

Text replacement - "0 mg" to "0mg"

← Revisión anterior		Revisión del 10:23 26 jul 2016
Línea 23:		Línea 23:
	*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for		*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for
	bleeding. ([[EBQ:Evidence Levels\|Level B]])		bleeding. ([[EBQ:Evidence Levels\|Level B]])
	*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of ~~600 mg~~, followed by a higher maintenance dose of ~~150 mg~~ daily for 6 days, then 75 mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])		*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600mg, followed by a higher maintenance dose of 150mg daily for 6 days, then 75 mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])

	==Summary of Class IIb Guidelines==		==Summary of Class IIb Guidelines==

Ostermayer: Text replacement - "Category:Cards" to "Category:Cardiology"

2016-03-22T13:53:03Z

Text replacement - "Category:Cards" to "Category:Cardiology"

← Revisión anterior		Revisión del 13:53 22 mar 2016
Línea 43:		Línea 43:
	<references/>		<references/>

	[[Category:~~Cards~~]]		[[Category:Cardiology]]

Rossdonaldson1 at 00:06, 27 August 2015

2015-08-27T00:06:41Z

Rossdonaldson1: /* Sources */

2014-09-30T13:39:47Z

Sources

← Revisión anterior		Revisión del 13:39 30 sep 2014
Línea 43:		Línea 43:

	<references/>		<references/>

			[[Category:Cards]]

← Revisión anterior		Revisión del 14:33 4 dic 2016
Línea 21:		Línea 21:
	*If an initial conservative strategy is selected, it may be reasonable to add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy.19,20 ([[EBQ:Evidence Levels\|Level B]])		*If an initial conservative strategy is selected, it may be reasonable to add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy.19,20 ([[EBQ:Evidence Levels\|Level B]])
	*Prasugrel may be considered for administration promptly upon presentation if PCI is planned, before definition of coronary anatomy if both the risk for bleeding is low and the need for CABG is considered unlikely. ([[EBQ:Evidence Levels\|Level C]])		*Prasugrel may be considered for administration promptly upon presentation if PCI is planned, before definition of coronary anatomy if both the risk for bleeding is low and the need for CABG is considered unlikely. ([[EBQ:Evidence Levels\|Level C]])
	*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for		*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated [[troponin]] levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for
	bleeding. ([[EBQ:Evidence Levels\|Level B]])		bleeding. ([[EBQ:Evidence Levels\|Level B]])
	*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600mg, followed by a higher maintenance dose of 150mg daily for 6 days, then 75mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])		*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600mg, followed by a higher maintenance dose of 150mg daily for 6 days, then 75mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])

← Revisión anterior		Revisión del 17:55 19 sep 2019
Línea 1:		Línea 1:
	==Summary of Class I Guidelines==		==Summary of Class I Guidelines==
	*Aspirin should be initiated as soon as possible and continued indefinitely in patients who tolerate it. ([[EBQ:Evidence Levels\|Level A]])		*[[Aspirin]] should be initiated as soon as possible and continued indefinitely in patients who tolerate it. ([[EBQ:Evidence Levels\|Level A]])
	*Clopidogrel loading dose should be initiated as soon as possible in patients unable to tolerate aspirin. ([[EBQ:Evidence Levels\|Level B]])		*[[Clopidogrel]] loading dose should be initiated as soon as possible in patients unable to tolerate aspirin. ([[EBQ:Evidence Levels\|Level B]])
	*Medium/High risk patients in whom initial invasive strategy is planned should receive dual therapy (Level A) including aspirin (Level A) and:		*Medium/High risk patients in whom initial invasive strategy is planned should receive dual therapy (Level A) including aspirin (Level A) and:
	**Before PCI one of the following:		**Before PCI one of the following:
Línea 9:		Línea 9:
	***Clopidogrel ([[EBQ:Evidence Levels\|Level A]]) if not started beforehand		***Clopidogrel ([[EBQ:Evidence Levels\|Level A]]) if not started beforehand
	***An IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) preferably eptifibatide or tirofiban.		***An IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) preferably eptifibatide or tirofiban.
	***Prasugrel ([[EBQ:Evidence Levels\|Level B]])		***[[Prasugrel]] ([[EBQ:Evidence Levels\|Level B]])
	*If an initial conservative (i.e. noninvasive) strategy is selected, clopidogrel should be added to ASA and anticoagulant therapy as soon as possible after admission. ([[EBQ:Evidence Levels\|Level B]])		*If an initial conservative (i.e. noninvasive) strategy is selected, clopidogrel should be added to ASA and anticoagulant therapy as soon as possible after admission. ([[EBQ:Evidence Levels\|Level B]])
	*If an initial conservative strategy is selected and recurrent symptoms/ischemia, heart failure, or serious arrhythmias subsequently appear, then diagnostic angiography should be performed. ([[EBQ:Evidence Levels\|Level A]]). Either an IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) or clopidogrel ([[EBQ:Evidence Levels\|Level B]]) should be added to ASA and anticoagulant therapy before diagnostic angiography. ([[EBQ:Evidence Levels\|Level C]])		*If an initial conservative strategy is selected and recurrent symptoms/ischemia, heart failure, or serious arrhythmias subsequently appear, then diagnostic angiography should be performed. ([[EBQ:Evidence Levels\|Level A]]). Either an IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) or clopidogrel ([[EBQ:Evidence Levels\|Level B]]) should be added to ASA and anticoagulant therapy before diagnostic angiography. ([[EBQ:Evidence Levels\|Level C]])

	==Summary of Class IIa Guidelines==		==Summary of Class IIa Guidelines==
	*If an initial conservative strategy is selected and patient has recurrent ischemic discomfort with clopidogrel, ASA, and anticoagulant therapy, it is reasonable to add a GP IIb/IIIa inhibitor before diagnostic angiography. ([[EBQ:Evidence Levels\|Level C]])		*If an initial conservative strategy is selected and patient has recurrent ischemic discomfort with clopidogrel, ASA, and [[anticoagulant]] therapy, it is reasonable to add a GP IIb/IIIa inhibitor before diagnostic angiography. ([[EBQ:Evidence Levels\|Level C]])
	*If an initial invasive strategy is selected, it is reasonable to omit administration of an IV GP IIb/IIIa inhibitor if bivalirudin is selected as the anticoagulant and clopidogrel was administered at least 6 hours earlier than planned catheterization or PCI. ([[EBQ:Evidence Levels\|Level B]])		*If an initial invasive strategy is selected, it is reasonable to omit administration of an IV GP IIb/IIIa inhibitor if [[bivalirudin]] is selected as the anticoagulant and clopidogrel was administered at least 6 hours earlier than planned catheterization or PCI. ([[EBQ:Evidence Levels\|Level B]])

	==Summary of Class IIb Guidelines==		==Summary of Class IIb Guidelines==

	*If an initial conservative strategy is selected, it may be reasonable to add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy.19,20 ([[EBQ:Evidence Levels\|Level B]])		*If an initial conservative strategy is selected, it may be reasonable to add [[eptifibatide]] or [[tirofiban]] to [[anticoagulant]] and oral antiplatelet therapy.19,20 ([[EBQ:Evidence Levels\|Level B]])
	*Prasugrel may be considered for administration promptly upon presentation if PCI is planned, before definition of coronary anatomy if both the risk for bleeding is low and the need for CABG is considered unlikely. ([[EBQ:Evidence Levels\|Level C]])		*Prasugrel may be considered for administration promptly upon presentation if PCI is planned, before definition of coronary anatomy if both the risk for bleeding is low and the need for CABG is considered unlikely. ([[EBQ:Evidence Levels\|Level C]])
	*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated [[troponin]] levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for		*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated [[troponin]] levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for

← Revisión anterior		Revisión del 00:06 27 ago 2015
Línea 1:		Línea 1:
	==Summary of Class I Guidelines==		==Summary of Class I Guidelines==
	#Aspirin should be initiated as soon as possible and continued indefinitely in patients who tolerate it. ([[EBQ:Evidence Levels\|Level A]])		*Aspirin should be initiated as soon as possible and continued indefinitely in patients who tolerate it. ([[EBQ:Evidence Levels\|Level A]])
	#Clopidogrel loading dose should be initiated as soon as possible in patients unable to tolerate aspirin. ([[EBQ:Evidence Levels\|Level B]])		*Clopidogrel loading dose should be initiated as soon as possible in patients unable to tolerate aspirin. ([[EBQ:Evidence Levels\|Level B]])
	#Medium/High risk patients in whom initial invasive strategy is planned should receive dual therapy (Level A) including aspirin (Level A) and:		*Medium/High risk patients in whom initial invasive strategy is planned should receive dual therapy (Level A) including aspirin (Level A) and:
	##Before PCI one of the following:		**Before PCI one of the following:
	~~###~~Clopidogrel ([[EBQ:Evidence Levels\|Level B]])		***Clopidogrel ([[EBQ:Evidence Levels\|Level B]])
	~~###~~An IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) preferably eptifibatide or tirofiban.		***An IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) preferably eptifibatide or tirofiban.
	##Otherwise during PCI one of the following:		**Otherwise during PCI one of the following:
	~~###~~Clopidogrel ([[EBQ:Evidence Levels\|Level A]]) if not started beforehand		***Clopidogrel ([[EBQ:Evidence Levels\|Level A]]) if not started beforehand
	~~###~~An IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) preferably eptifibatide or tirofiban.		***An IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) preferably eptifibatide or tirofiban.
	~~###~~Prasugrel ([[EBQ:Evidence Levels\|Level B]])		***Prasugrel ([[EBQ:Evidence Levels\|Level B]])
	#If an initial conservative (i.e. noninvasive) strategy is selected, clopidogrel should be added to ASA and anticoagulant therapy as soon as possible after admission. ([[EBQ:Evidence Levels\|Level B]])		*If an initial conservative (i.e. noninvasive) strategy is selected, clopidogrel should be added to ASA and anticoagulant therapy as soon as possible after admission. ([[EBQ:Evidence Levels\|Level B]])
	#If an initial conservative strategy is selected and recurrent symptoms/ischemia, heart failure, or serious arrhythmias subsequently appear, then diagnostic angiography should be performed. ([[EBQ:Evidence Levels\|Level A]]). Either an IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) or clopidogrel ([[EBQ:Evidence Levels\|Level B]]) should be added to ASA and anticoagulant therapy before diagnostic angiography. ([[EBQ:Evidence Levels\|Level C]])		*If an initial conservative strategy is selected and recurrent symptoms/ischemia, heart failure, or serious arrhythmias subsequently appear, then diagnostic angiography should be performed. ([[EBQ:Evidence Levels\|Level A]]). Either an IV GP IIb/IIIa inhibitor ([[EBQ:Evidence Levels\|Level A]]) or clopidogrel ([[EBQ:Evidence Levels\|Level B]]) should be added to ASA and anticoagulant therapy before diagnostic angiography. ([[EBQ:Evidence Levels\|Level C]])

	==Summary of Class IIa Guidelines==		==Summary of Class IIa Guidelines==
	#If an initial conservative strategy is selected and patient has recurrent ischemic discomfort with clopidogrel, ASA, and anticoagulant therapy, it is reasonable to add a GP IIb/IIIa inhibitor before diagnostic angiography. ([[EBQ:Evidence Levels\|Level C]])		*If an initial conservative strategy is selected and patient has recurrent ischemic discomfort with clopidogrel, ASA, and anticoagulant therapy, it is reasonable to add a GP IIb/IIIa inhibitor before diagnostic angiography. ([[EBQ:Evidence Levels\|Level C]])
	#If an initial invasive strategy is selected, it is reasonable to omit administration of an IV GP IIb/IIIa inhibitor if bivalirudin is selected as the anticoagulant and clopidogrel was administered at least 6 hours earlier than planned catheterization or PCI. ([[EBQ:Evidence Levels\|Level B]])		*If an initial invasive strategy is selected, it is reasonable to omit administration of an IV GP IIb/IIIa inhibitor if bivalirudin is selected as the anticoagulant and clopidogrel was administered at least 6 hours earlier than planned catheterization or PCI. ([[EBQ:Evidence Levels\|Level B]])

	==Summary of Class IIb Guidelines==		==Summary of Class IIb Guidelines==

	#If an initial conservative strategy is selected, it may be reasonable to add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy.19,20 ([[EBQ:Evidence Levels\|Level B]])		*If an initial conservative strategy is selected, it may be reasonable to add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy.19,20 ([[EBQ:Evidence Levels\|Level B]])
	#Prasugrel may be considered for administration promptly upon presentation if PCI is planned, before definition of coronary anatomy if both the risk for bleeding is low and the need for CABG is considered unlikely. ([[EBQ:Evidence Levels\|Level C]])		*Prasugrel may be considered for administration promptly upon presentation if PCI is planned, before definition of coronary anatomy if both the risk for bleeding is low and the need for CABG is considered unlikely. ([[EBQ:Evidence Levels\|Level C]])
	#The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for		*The use of GP IIb/IIIa inhibitors may be considered in high-risk patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for
	bleeding. ([[EBQ:Evidence Levels\|Level B]])		bleeding. ([[EBQ:Evidence Levels\|Level B]])
	#In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600 mg, followed by a higher maintenance dose of 150 mg daily for 6 days, then 75 mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])		*In patients with definite UA/NSTEMI undergoing PCI, the use of a loading dose of clopidogrel of 600 mg, followed by a higher maintenance dose of 150 mg daily for 6 days, then 75 mg daily may be reasonable in patients not considered at high risk for bleeding. ([[EBQ:Evidence Levels\|Level B]])

	==Summary of Class IIb Guidelines==		==Summary of Class IIb Guidelines==

	#Abciximab should not be administered to patients in whom PCI is not planned. ([[EBQ:Evidence Levels\|Level A]])		*Abciximab should not be administered to patients in whom PCI is not planned. ([[EBQ:Evidence Levels\|Level A]])
	#Low risk patients for ischemic events (TIMI risk score 2) or at high risk of bleeding and who are already receiving ASA and clopidogrel, upstream GP IIb/IIIa inhibitors are not recommended. ([[EBQ:Evidence Levels\|Level B]])		*Low risk patients for ischemic events (TIMI risk score 2) or at high risk of bleeding and who are already receiving ASA and clopidogrel, upstream GP IIb/IIIa inhibitors are not recommended. ([[EBQ:Evidence Levels\|Level B]])

	==Summary of Class III Guidelines==		==Summary of Class III Guidelines==

	#In UA/NSTEMI patients with a prior history of stroke or TIA for whom PCI is planned, prasugrel is potentially harmful as part of a dual-antiplatelet therapy regimen.([[EBQ:Evidence Levels\|Level B]])		*In UA/NSTEMI patients with a prior history of stroke or TIA for whom PCI is planned, prasugrel is potentially harmful as part of a dual-antiplatelet therapy regimen.([[EBQ:Evidence Levels\|Level B]])

	==See Also==		==See Also==
Línea 39:		Línea 39:
	*[[Recommendation Grading System]]		*[[Recommendation Grading System]]

	==~~Sources~~==		==References==
	[https://circ.ahajournals.org/content/123/18/2022.full.pdf 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non −ST-Elevation Myocardial Infarction. Circulation 2011;123:2022-2060.]		[https://circ.ahajournals.org/content/123/18/2022.full.pdf 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non −ST-Elevation Myocardial Infarction. Circulation 2011;123:2022-2060.]

	<references/>		<references/>

	[[Category:Cards]]		[[Category:Cards]]